Humana (NYSE:HUM – Get Free Report) updated its FY 2026 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of 9.500- for the period, compared to the consensus earnings per share estimate of 9.130. The company issued revenue guidance of $160.0 billion, compared to the consensus revenue estimate of $162.5 billion.
Humana Price Performance
NYSE:HUM opened at $432.69 on Friday. The stock has a market capitalization of $51.96 billion, a PE ratio of 42.09, a P/E/G ratio of 2.67 and a beta of 0.65. Humana has a 1-year low of $163.11 and a 1-year high of $456.50. The firm has a fifty day simple moving average of $403.96 and a 200 day simple moving average of $312.27. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.62.
Humana (NYSE:HUM – Get Free Report) last announced its quarterly earnings results on Friday, November 6th. The insurance provider reported ($0.70) EPS for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.30. The firm had revenue of $41.16 billion during the quarter, compared to analysts’ expectations of $40.87 billion. Humana had a net margin of 0.88% and a return on equity of 11.20%. The company’s revenue for the quarter was up 26.1% compared to the same quarter last year. During the same quarter last year, the company posted $3.24 earnings per share. Humana has set its FY 2026 guidance at 9.500- EPS. On average, research analysts expect that Humana will post 9.03 EPS for the current fiscal year.
Humana Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Friday, January 29th. Investors of record on Thursday, December 24th will be issued a dividend of $0.8850 per share. The ex-dividend date is Thursday, December 24th. This represents a $3.54 dividend on an annualized basis and a yield of 0.8%. Humana’s dividend payout ratio (DPR) is presently 34.44%.
Wall Street Analysts Forecast Growth
A number of analysts have recently issued reports on HUM shares. Wells Fargo & Company raised Humana from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $227.00 to $502.00 in a research report on Monday, July 13th. Mizuho boosted their target price on Humana from $468.00 to $495.00 and gave the stock an “outperform” rating in a report on Tuesday, October 13th. JPMorgan Chase & Co. raised their price target on Humana from $316.00 to $393.00 and gave the company a “neutral” rating in a report on Monday, August 10th. TD Cowen lifted their price objective on shares of Humana from $350.00 to $370.00 and gave the stock a “hold” rating in a research report on Friday, July 31st. Finally, Piper Sandler raised shares of Humana from a “hold” rating to an “overweight” rating and set a $463.00 price objective for the company in a research report on Thursday, July 30th. Twenty-one analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $458.96.
Check Out Our Latest Analysis on HUM
Key Stories Impacting Humana
Here are the key news stories impacting Humana this week:
- Positive Sentiment: Humana reported a third-quarter loss of $0.70 per share, narrower than analysts’ expected $1.00 loss. Revenue rose 26.1% year over year to $41.16 billion, topping estimates. Article: HUM Q3 Earnings Beat Estimates on Strong Insurance Performance
- Positive Sentiment: The company raised its full-year 2026 adjusted EPS forecast to at least $9.50, above the roughly $9.13 consensus estimate. Reports cited lower-than-expected medical costs as a factor supporting the improved outlook. Article: Humana Raises 2026 Earnings Outlook
- Positive Sentiment: Humana expects Medicare Advantage membership to grow again in 2027, signaling continued expansion in a key business. Its CenterWell unit also helped drive the quarterly performance. Article: Humana Expects Another Year of Medicare Advantage Membership Growth
- Neutral Sentiment: Humana’s 2026 revenue guidance of $160 billion was below analysts’ $162.5 billion estimate, tempering the otherwise favorable earnings and outlook news. Article: Humana Third-Quarter Earnings
- Negative Sentiment: Despite beating estimates, Humana posted a loss compared with earnings of $3.24 per share a year earlier. Reports also noted that costs associated with new Medicare enrollees remain a concern. Article: Humana Profits Dip as Costs Rise from New Medicare Enrollees
Humana Company Profile
Humana Inc is a U.S. health and wellness company that provides health insurance and healthcare services. Its insurance offerings include Medicare Advantage, Medicare Supplement and prescription drug plans, as well as Medicaid and employer-sponsored plans.
The company also provides care through CenterWell, its healthcare services brand, which includes primary care, home health and pharmacy services. Its insurance and care offerings are available in markets across the United States, with availability varying by product and location.
Humana was founded in 1961 as a nursing home company and later expanded into health insurance.
Featured Stories
- Five stocks we like better than Humana
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.
